Skip to main content
SpringerLink
Log in

Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia

  • Chapter
Combination Therapy In Dyslipidemia

Abstract

Lipid management guidelines promulgated around the world continue to emphasize the need to reduce serum levels of low-density lipoprotein cholesterol (LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is greater and greater benefit as LDL-C decreases with no apparent loss in safety [4–8]. Dyslipidemia and coronary artery disease (CAD) are widely prevalent throughout the world. Considerable effort continues to be focused on expanding the appropriate use of lipid-lowering medication in order to more optimally reduce the burden of atherogenic lipoproteins in serum.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45.

    Article  PubMed  Google Scholar 

  2. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.

    Article  PubMed  Google Scholar 

  3. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25:567–79.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer M, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy a Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) substudy. J Am Coll Cardiol. 2005;46(8):1411–6.

    Article  CAS  PubMed  Google Scholar 

  5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.

    Article  CAS  PubMed  Google Scholar 

  6. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45.

    Article  CAS  PubMed  Google Scholar 

  7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.

    Article  CAS  PubMed  Google Scholar 

  8. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7, e29849.

    Article  CAS  PubMed  Google Scholar 

  9. Shammas N, Lemke J, Deckert J, Toth P, McKinney D, Dippel E. Gender differences in adhering to national guidelines in a community lipid clinic. Prev Cardiol. 2006;9:215–8.

    Article  CAS  PubMed  Google Scholar 

  10. Peter PT, Victoria Z, Jane MS, Dave L. Lipid therapy utilization rates in a managed-care mixed dyslipidemia population. J Clin Lipidol. 2008;2:365–74.

    Article  Google Scholar 

  11. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–63.

    Article  PubMed  Google Scholar 

  12. Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev Cardiovasc Ther. 2006;4:283–91.

    Article  CAS  PubMed  Google Scholar 

  13. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–61.

    Article  CAS  PubMed  Google Scholar 

  14. Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci. 2015;72:1631–50.

    Article  CAS  PubMed  Google Scholar 

  15. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol. 2012;23:43–55.

    Article  CAS  PubMed  Google Scholar 

  16. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–26.

    Article  CAS  PubMed  Google Scholar 

  17. Shepherd J, Packard CJ, Bicker S, Lawrie TD, Morgan HG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980;302:1219–22.

    Article  CAS  PubMed  Google Scholar 

  18. Donovan JM, Von Bergmann K, Setchell KD, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci. 2005;50:1232–8.

    Article  CAS  PubMed  Google Scholar 

  19. Grundy SM, Ahrens Jr EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971;78:94–121.

    CAS  PubMed  Google Scholar 

  20. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97:1198–205.

    Article  CAS  PubMed  Google Scholar 

  21. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24:467–74.

    Article  CAS  PubMed  Google Scholar 

  22. Hunninghake D, Insull Jr W, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407–16.

    Article  CAS  PubMed  Google Scholar 

  23. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110:352–60.

    Article  CAS  PubMed  Google Scholar 

  24. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22:2191–200.

    Article  CAS  PubMed  Google Scholar 

  25. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21:1403–12.

    Article  CAS  PubMed  Google Scholar 

  26. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis. 2009;204:342–4.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006;185(2):327–30.

    Article  CAS  PubMed  Google Scholar 

  28. Merten DF, Grossman H. Intestinal obstruction associated with cholestyramine therapy. AJR Am J Roentgenol. 1980;134:827–8.

    Article  CAS  PubMed  Google Scholar 

  29. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.

    Google Scholar 

  30. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–74.

    Google Scholar 

  31. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313–24.

    Article  CAS  PubMed  Google Scholar 

  32. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–40.

    Article  CAS  PubMed  Google Scholar 

  33. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013–7.

    Article  CAS  PubMed  Google Scholar 

  34. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.

    Article  CAS  PubMed  Google Scholar 

  35. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–12.

    Article  CAS  PubMed  Google Scholar 

  36. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563–9.

    Article  CAS  PubMed  Google Scholar 

  37. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med. 1994;121:416–22.

    Article  CAS  PubMed  Google Scholar 

  38. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J. 2007;54:53–8.

    Article  CAS  PubMed  Google Scholar 

  39. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74–83.

    Article  CAS  PubMed  Google Scholar 

  40. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168:1975–83.

    Article  CAS  PubMed  Google Scholar 

  41. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531–40.

    Article  CAS  PubMed  Google Scholar 

  42. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem. 2003;278:39124–32.

    Article  PubMed  Google Scholar 

  44. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146:984–91.

    Article  CAS  PubMed  Google Scholar 

  45. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279:23158–65.

    Article  CAS  PubMed  Google Scholar 

  46. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714–9.

    Article  CAS  PubMed  Google Scholar 

  47. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435–40.

    Article  CAS  PubMed  Google Scholar 

  48. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord. 2010;8 Suppl 1:S3–8.

    CAS  PubMed  Google Scholar 

  49. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011;13:729–38.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res. 2009;50:S120–5.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preventive Cardiology, CGH Medical Center, 101 East Miller Road, Sterling, IL, 61081, USA

    Peter P. Toth MD, PhD

  2. Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL, USA

    Peter P. Toth MD, PhD

  3. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth MD, PhD

  4. BioMedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

    Dragana Nikolic & Manfredi Rizz

  5. Euro-Mediterranean Institute of Science and Technology, Palermo, Italy

    Manfredi Rizz

  6. Department of Hypertension, Medical University of Lodz, Lodz, Poland

    Jacek Rysz & Maciej Banach

Authors
  1. Peter P. Toth MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dragana Nikolic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfredi Rizz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacek Rysz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maciej Banach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter P. Toth MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    Maciej Banach

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Toth, P.P., Nikolic, D., Rizz, M., Rysz, J., Banach, M. (2015). Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. In: Banach, M. (eds) Combination Therapy In Dyslipidemia. Adis, Cham. https://doi.org/10.1007/978-3-319-20433-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20433-8_1

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20432-1

  • Online ISBN: 978-3-319-20433-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation